Drug Profile
RO 5095932
Alternative Names: RO-5095932Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Roche
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 07 Aug 2013 No development reported - Phase-I for Type-2 diabetes mellitus in USA (SC)
- 31 Aug 2011 Roche completes a Phase-I trial in Type 2 diabetes mellitus in USA (NCT00961909)
- 31 Aug 2011 Roche completes a phase I trial in Type 2 diabetes mellitus in USA (NCT01017302)